Skip to main content
. 2013 Nov 1;5(Suppl 1):47–55. doi: 10.2147/CLEP.S47153

Table 2.

Proportion of prostate cancer cases by individual Charlson comorbidities

Charlson comorbidity diseases Total period
Calendar period of registration of comorbidity diseases (%)
2000–2011 2000–2002 2003–2005 2006–2008 2009–2011
Cerebrovascular disease 717 (9.4) 106 (8.7) 165 (9.8) 232 (10.0) 214 (8.8)
Chronic pulmonary disease 578 (7.6) 126 (10.3) 149 (8.9) 151 (6.5) 152 (6.2)
Any tumor 472 (6.2) 83 (6.8) 114 (6.8) 129 (5.6) 146 (6.0)
Myocardial infarction 472 (6.2) 73 (6.0) 108 (6.4) 131 (5.7) 160 (6.6)
Peripheral vascular disease 406 (5.3) 81 (6.6) 84 (5.0) 133 (5.7) 108 (4.4)
Congestive heart failure 378 (4.9) 82 (6.7) 95 (5.7) 106 (4.6) 95 (3.9)
Ulcer disease 267 (3.5) 52 (4.3) 79 (4.7) 68 (2.9) 68 (2.8)
Diabetes (type I and II) 251 (3.3) 47 (3.9) 55 (3.3) 71 (3.1) 78 (3.2)
Moderate-to-severe renal disease 203 (2.7) 32 (2.6) 59 (3.5) 41 (1.8) 71 (2.9)
Diabetes with end organ disease 179 (2.3) 41 (3.4) 31 (1.8) 44 (1.9) 63 (2.6)
Connective tissue disease 182 (2.4) 26 (2.1) 38 (2.3) 57 (2.5) 61 (2.5)
Metastatic solid tumor 51 (0.7) 3 (0.2) 9 (0.5) 15 (0.6) 24 (1.0)
Dementia 46 (0.6) 9 (0.7) 9 (0.5) 15 (0.6) 13 (0.5)
Mild liver disease 31 (0.4) 5 (0.4) 7 (0.4) 16 (0.7) 3 (0.1)
Lymphoma 30 (0.4) 6 (0.5) 10 (0.6) 7 (0.3) 7 (0.3)
Leukemia 11 (0.1) 1 (0.1) 5 (0.3) 2 (0.1) 3 (0.1)
Hemiplegia 9 (0.1) 0 1 (0.1) 2 (0.1) 6 (0.2)
Moderate-to-severe liver disease 8 (0.1) 1 (0.1) 2 (0.1) 3 (0.1) 2 (0.1)
HIV/AIDS 2 (0.0) 0 0 0 2 (0.1)

Note: Data are presented as n (%).